Ibrutinib treatment partially restores chromatin signatures at gained enhancers in CLL. (A) Comparison of the log₂ fold changes of the genes regulated by decreased enhancers in CLL between CLL vs NBCs and ibrutinib treatment vs baseline CLL B cells. (B) Expression of IL-6 in the indicated samples. (C) Comparison of the log₂ fold changes of the genes regulated by increased enhancers in CLL between CLL vs NBCs and ibrutinib treatment vs baseline CLL B cells. (D) Expression of LEF1 in the indicated samples. (E) Representative metagene heat map showing the CLL-gained and -lost enhancers in the CLL B cells derived from patients with CLL at baseline and during ibrutinib treatment. (F-G) Representative snapshots showing the indicated histone marks at the LEF1 and IL-6 gene loci. ns, not significant.